Skip to main content
. Author manuscript; available in PMC: 2013 Aug 27.
Published in final edited form as: Differentiation. 2011 Mar 17;81(4):233–242. doi: 10.1016/j.diff.2011.02.005

Figure 2.

Figure 2

Comparison of 1's effects in primary mouse astrocytes carrying glioma-relevant mutations. (A-E) Representative images of vehicle or 1-treated astrocytes with indicated Ink4a/Arf; Pten; EGFRvIII genotypes or wild-type (wt) astrocytes and immunostaining for Ki67 in 4-day cultures. (F-J) Representative images of vehicle or 1-treated astrocytes with indicated Ink4a/Arf; Pten; EGFRvIII genotypes or wild-type (wt) astrocytes and immunostaining for Tuj1 or GFAP in 4-day cultures. Scale bar: 25 μm. (K-N) Quantification of Ki67+ or Tuj1+ primary astrocytes after 4 days of vehicle or 1 treatment is shown. (**p < 0.001, t-test, data in graphs represent ± s.d. from three independent experiments).